Mitochondria and neurodegenerative diseases: the promising role of nanotechnology in targeted drug delivery.
Neurodegenerative diseases (NDs) represent a group of different clinical entities that, despite the specific primary etiologies, share a common signature in terms of a general mitochondrial dysfunction with consequent oxidative stress accumulation. As these two events occur early during neurodegenerative process, they could be considered ideal therapeutic targets. Areas covered: This review describes the nanotechnologies explored for the specific targeted delivery of drugs, in order to precisely direct molecules into the intended site, where they can practice their therapeutic effects. Expert opinion: Conventional drug delivery systems cannot provide adequate restoration and connection patterns that are essential for a functional recovery in NDs. Since orally delivered antioxidants are easily destroyed by acids and enzymes, only a small portion of consumed antioxidants gets absorbed, leading to low bioavailability and low concentration at the target site. In this scenario, the identification of new proenergetic drugs, in combination with the development of methods for selectively delivering biologically active molecules into mitochondria, will potentially launch new therapeutic approaches for the treatment of NDs, where energetic imbalance plays a central role.
['Pezzini|Ilaria|I|', 'Mattoli|Virgilio|V|', 'Ciofani|Gianni|G|']
D000818:Animals D000975:Antioxidants D016503:Drug Delivery Systems D006801:Humans D008928:Mitochondria D036103:Nanotechnology D019636:Neurodegenerative Diseases D018384:Oxidative Stress D004364:Pharmaceutical Preparations
Neurodegenerative diseases oxidative stress ROS drug targeting mitochondrial targeting nanomedicine